Researchers we fund are outstanding scientists
at the forefront of leukemia, lymphoma, myeloma, MDS, and MPNs research at cancer centres throughout Canada. We award grants for studies that will advance our mission to find cures for blood cancers and improve the quality of life of those affected by blood cancer. These studies range from basic research projects that will lead to a better understanding of blood cancers, to translational research projects that show high promise for translating basic biomedical knowledge to clinical application.
Our competitions
Physician Scientist Fellow Award (formerly Clinician Scientist Fellow Award)
Letter of Intent (LOI) due October 26, 2023, 4:00 pm EST.
The intent of the Physician Scientist Fellow Award is to encourage early-stage specialist clinicians to pursue a career in blood cancer research.
The intent of the Physician Scientist Fellow Award is to encourage early-stage specialist clinicians to pursue a career in blood cancer research.
Blood Cancer Quality of Life Grant
Letter of Intent (LOI) due October 26, 2023, 4:00 pm EST.
The intent of this funding opportunity is to support new research designed to address quality of life challenges experienced by Canadians affected by blood cancers.
The intent of this funding opportunity is to support new research designed to address quality of life challenges experienced by Canadians affected by blood cancers.
Pediatric Blood Cancer Research Innovation Grant
Letter of Intent (LOI) due October 26, 2023, 4:00 pm EST.
This grant is designed to challenge the current pediatric blood cancer landscape by providing funding for projects that will address unmet needs for pediatric blood cancers.
This grant is designed to challenge the current pediatric blood cancer landscape by providing funding for projects that will address unmet needs for pediatric blood cancers.
Operating grant
Letter of Intent (LOI) due October 26, 2023, 4:00 pm EST.
The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancer.
The Operating Grant is a two-year grant designed to provide funding to research that may ultimately lead to a significant change in the understanding, diagnosis, or treatment of blood cancer.
Translational Research Program
Letter of Intent (LOI) due October 20, 2023
These grants fund new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application.
These grants fund new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application.
Canadian researchers may also apply for grants funded by The Leukemia & Lymphoma Society (LLS) based in the US. Please check the following link for information regarding competition guidelines and deadlines. You will be redirected to the website of The Leukemia & Lymphoma Society in the United States.